Total Investment Management Inc. reduced its position in Pfizer, Inc. (NYSE:PFE) by 2.9% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 6,649 shares of the biopharmaceutical company’s stock after selling 201 shares during the quarter. Total Investment Management Inc.’s holdings in Pfizer were worth $223,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of the company. D. Scott Neal Inc. lifted its position in shares of Pfizer by 19.3% during the 2nd quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock valued at $105,000 after acquiring an additional 504 shares during the period. Franklin Parlapiano Turner & Welch LLC acquired a new position in shares of Pfizer during the 1st quarter valued at $121,000. Cascade Investment Advisors Inc. lifted its position in shares of Pfizer by 89.1% during the 2nd quarter. Cascade Investment Advisors Inc. now owns 4,669 shares of the biopharmaceutical company’s stock valued at $157,000 after acquiring an additional 2,200 shares during the period. Patten Group Inc. lifted its position in shares of Pfizer by 5.1% during the 1st quarter. Patten Group Inc. now owns 5,181 shares of the biopharmaceutical company’s stock valued at $177,000 after acquiring an additional 252 shares during the period. Finally, Acropolis Investment Management LLC lifted its position in shares of Pfizer by 6.7% during the 2nd quarter. Acropolis Investment Management LLC now owns 5,603 shares of the biopharmaceutical company’s stock valued at $188,000 after acquiring an additional 352 shares during the period. 68.98% of the stock is currently owned by institutional investors.

A number of research analysts recently issued reports on PFE shares. Cowen and Company set a $43.00 target price on shares of Pfizer and gave the company a “buy” rating in a research report on Monday, August 14th. Jefferies Group LLC set a $35.00 target price on shares of Pfizer and gave the company a “neutral” rating in a research report on Thursday, August 24th. Berenberg Bank reiterated a “hold” rating and set a $36.00 target price (down previously from $39.00) on shares of Pfizer in a research report on Tuesday, August 15th. Deutsche Bank AG set a $38.00 target price on shares of Pfizer and gave the company a “buy” rating in a research report on Wednesday, October 11th. Finally, BidaskClub downgraded shares of Pfizer from a “sell” rating to a “strong sell” rating in a research report on Thursday, July 13th. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and twelve have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $38.26.

Shares of Pfizer, Inc. (NYSE:PFE) opened at 36.42 on Friday. The stock has a market cap of $216.60 billion, a P/E ratio of 26.64 and a beta of 1.00. The stock has a 50 day moving average of $35.56 and a 200 day moving average of $33.83. Pfizer, Inc. has a one year low of $29.83 and a one year high of $36.60.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.65 by $0.02. Pfizer had a return on equity of 24.51% and a net margin of 15.84%. The business had revenue of $12.90 billion during the quarter, compared to analyst estimates of $13.08 billion. During the same quarter in the previous year, the firm earned $0.64 EPS. Pfizer’s revenue was down 1.9% on a year-over-year basis. On average, analysts forecast that Pfizer, Inc. will post $2.56 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, December 1st. Shareholders of record on Friday, November 10th will be given a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a yield of 3.51%. The ex-dividend date is Thursday, November 9th. Pfizer’s dividend payout ratio (DPR) is 94.12%.

In other Pfizer news, insider Laurie J. Olson sold 8,064 shares of the business’s stock in a transaction dated Monday, August 21st. The stock was sold at an average price of $32.70, for a total value of $263,692.80. Following the completion of the transaction, the insider now owns 74,506 shares of the company’s stock, valued at approximately $2,436,346.20. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Alexander R. Mackenzie sold 15,000 shares of the business’s stock in a transaction dated Monday, August 7th. The stock was sold at an average price of $33.50, for a total value of $502,500.00. Following the completion of the transaction, the insider now directly owns 151,474 shares of the company’s stock, valued at approximately $5,074,379. The disclosure for this sale can be found here. In the last three months, insiders sold 464,521 shares of company stock valued at $15,813,961. 0.06% of the stock is owned by insiders.

TRADEMARK VIOLATION WARNING: This news story was reported by Daily Political and is owned by of Daily Political. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of United States and international trademark & copyright legislation. The legal version of this news story can be viewed at https://www.dailypolitical.com/2017/10/22/total-investment-management-inc-has-223000-stake-in-pfizer-inc-pfe.html.

Pfizer Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.